Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002332 · ClinicalTrials.gov registry record · Phase 2
A Study of Timunox (Thymopentin) in HIV-Infected Patients Receiving Other Anti-HIV Drugs
A Phase 2 study of HIV Infections, sponsored by Immunobiology Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 3
- Study locations
NCT00002332: Completed Phase 2 study of HIV Infections, sponsored by Immunobiology Research Institute.
NCT00002332 is a Phase 2 study of HIV Infections that has completed, run by Immunobiology Research Institute. The registered enrollment target is 60 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (87% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002332, a Phase 2 study of HIV Infections, has completed, sponsored by Immunobiology Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 3
- Study locations
Study Summary
To evaluate the mechanism whereby thymopentin appears to retard the progressive immune suppression attributable to HIV infection.
Conditions Studied
Interventions
- DRUG Thymopentin
Study Locations (3)
California
- Dr Marcus Conant - San Francisco
- Dr Jeffrey Galpin - Tarzana
Pennsylvania
- Novum Inc - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002332
The ClinicalTrials.gov registry entry for NCT00002332 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (87% lower). The listed sponsor is Immunobiology Research Institute, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Thymopentin is the first listed.
NCT00002332 reports 3 study locations spanning 2 distinct geographic areas - top geographies include California, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00002332 about?
NCT00002332 is a clinical study titled "A Study of Timunox (Thymopentin) in HIV-Infected Patients Receiving Other Anti-HIV Drugs". To evaluate the mechanism whereby thymopentin appears to retard the progressive immune suppression attributable to HIV infection.
What is the current status of trial NCT00002332?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants.
What conditions does trial NCT00002332 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00002332?
The interventions under investigation include: Thymopentin (DRUG).
Who is sponsoring clinical trial NCT00002332?
This trial is sponsored by Immunobiology Research Institute, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002332 being conducted?
This trial has 3 study locations across California, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.